Scrip
>>R&D

Ebola Outbreak In DR Congo: Where Are The Vaccines In Development?

16 May 2018

Following reports of another Ebola outbreak in Africa, Scrip explores the pipeline of clinical-stage vaccines and how the companies developing immunizations are approaching the most recent cases of the viral hemorrhagic disease.

Syringes — The vaccines being advanced to tackle a new Ebola outbreak in Africa • Source: Shutterstock

Another outbreak of Ebola, this time in the Democratic Republic of the Congo (DR Congo), could spur pharma into action once more after a quiet period since the 2014/2015 epidemic in West Africa.

The government of DR Congo declared a new outbreak of Ebola virus disease in Bikoro, Equateur Province, in early May. It is the region’s ninth outbreak of Ebola since the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.